Category Archives: Cell Biology

Cell Biology

Scaffold Technology Market 2020 With COVID-19 Impact Analysis, Business Opportunities and Future Outlook 2026 – Cole of Duty

The Global Scaffold Technology Market report is a comprehensive analysis of different market factors and conditions that can decide the growth of the market. The Scaffold Technology report is a valuable source of information to different individuals and organizations that are interested in either entering the Scaffold Technology industry or in identifying new and innovative methods of increasing the revenue earned. These trends are categorized based on their popularity and are presented in the report. The Scaffold Technology market is further divided into different market segments.

Request for Sample at

https://www.marketinsightsreports.com/reports/04242002639/global-scaffold-technology-market-size-status-and-forecast-2020-2026/inquiry?Source=mw&mode=52

Scaffold Technology Market is anticipated to grow at a CAGR of 10.37% from 2019 to 2026

Scaffold Technology is primarily tissue engineering, evolving into biological alternatives, with applications for replacing, regenerating and repairing diseased or defective organs or tissues.Key factors such as the increase in medical expenditures, the improvement of the medical system, and the increase in R&D investment account for a large proportion in North America. As healthcare organizations continue to increase their understanding of this technology, companies in the Asia Pacific region are expected to drive industry expansion in the future

The prominent players are

NuVasive, 3D Biomatrix, Akron Biotech, Arterial Remodeling Technologies S.A., Matricel, Molecular Matrix, Nanofiber Solutions, ReproCELL

Scaffold Technology Breakdown Data by TypeCell Attachment and MigrationNutrients and Products DiffusionCell Phase Behavior ModificationOther

Scaffold Technology Breakdown Data by ApplicationPharmaceuticalsResearch Laboratories and InstitutesHospitalsDiagnostic CentersOther

Scaffold Technology seeks a persistent evolution of technology with dependence on cellular biology that brings to the fore biological substitutes for regenerative action by taking on diseased organs or tissues. This technology also brings to the fore in vivo and in vitro tissue regeneration within synthetic polymeric scaffolds. scaffold technology is divided into drug development, stem cell research, cancer, tissue engineering and clinical application and others

SPECIAL OFFER GET UPTO 15% DISCOUNT ON THIS REPORT

Get discount on this report

https://www.marketinsightsreports.com/reports/04242002639/global-scaffold-technology-market-size-status-and-forecast-2020-2026/discount?Source=mw&mode=52

This report provides insights on the following pointers:

Browse this Report

https://www.marketinsightsreports.com/reports/04242002639/global-scaffold-technology-market-size-status-and-forecast-2020-2026?Source=mw&mode=52

Contact Us

Irfan Tamboli (Head of Sales) Market Insights Reports

Phone: + 1704 266 3234 | +91-750-707-8687

[emailprotected]

[emailprotected]

Go here to read the rest:
Scaffold Technology Market 2020 With COVID-19 Impact Analysis, Business Opportunities and Future Outlook 2026 - Cole of Duty

Cell Biology

Genespire and SR-Tiget announce strategic alliance for the development of transformative gene therapies for genetic diseases and disclose collaboratio…

Pre-clinical data from SR-Tiget, included in the alliance with Genespire, to be presented at ASGCT 23rd Annual Meeting

Italy, Milan, 13 May 2020: The San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), one of the worlds leading gene therapy research institutes jointly managed by Fondazione Telethon and Ospedale San Raffaele and Genespire, a gene therapy company developing transformative therapies for genetic diseases, and spin-out of SR-Tiget, announced today their alliance on the research and development of candidate therapeutic products for people affected by primary immunodeficiencies and metabolic diseases based on novel gene editing and lentiviral vector technologies developed by SR-Tiget.

Genespire was co-founded in March 2020 by SR-Tiget director and gene therapy pioneer Prof. Luigi Naldini and Dr. Alessio Cantore, Fondazione Telethon and Ospedale San Raffaele. Genespire recently raised 16 million in a Series A financing round from Sofinnova Partners.

Under the terms of the alliance, Genespire and SR-Tiget will study and further develop novel gene therapies, which have the unique potential to address severe unmet medical need and exploit gene editing and lentiviral vector technologies developed by SR-Tiget.

Genespire was granted an exclusive global license for the research, development and commercialization of gene therapies for metabolic diseases based on SR-Tigets alloantigen free, microRNA-regulated lentiviral vectors, which allow for stable liver gene therapy even for diseases with early onset, requiring administration at a young age.

Genespire was also granted exclusive licenses and options to the results of a joint research and development program with SR-Tiget in the T-cell and Hematopoietic Stem Cells field to address genetic diseases, in particular primary immunodeficiencies, exploiting the ex vivo gene editing technology. SR-Tiget and Genespire will first collaborate to bring an ex-vivo autologous edited T-cell gene therapy for X-linked Hyper IgM syndrome (HIGM1) to the clinic, which becomes Genespires lead candidate product. HIGM1 is caused by inherited mutations of the CD40 ligand gene (CD40L), resulting in impaired antibody response and innate immunity, meaning that people find it difficult to fight off infections and eventually succumb to them. The treatment objective is to correct the defective gene through targeted editing of the endogenous locus, thereby maintaining physiological regulation of the CD40L gene, with the aim of improving the immune response of the patients.

Preclinical results of SR-Tiget on HIGM1 will be disclosed in an oral presentation at the American Society for Cell and Gene Therapy (ASGCT) 23rd Annual Meeting, taking place virtually from 12-15 May 2020 by SR-Tiget (details of Presentation 1 below). The presentation will outline the technology and its preclinical validation in the disease model and patient derived cells and discuss the potential of the gene edited T-cell treatment approach for patients with Hyper IgM.

Dr. Alessio Cantore will also present novel data related to the potential of the lentiviral vector platform for liver gene therapy in an oral presentation at ASGCT (details of Presentation 2 below). The presentation will focus on investigating the stability of lentiviral vector genetically modified liver cells following post-natal liver growth in mice, in view of its potential application to pediatric patients.

Luigi Naldini, Director of SR-Tiget and scientific co-founder of Genespire said: We are excited to have secured a path for bringing forward some of the gene therapy work pioneered at SR-Tiget to eventually help individuals affected by severe metabolic and immunodeficiency disorders. SR-Tigets alliance with Genespire will provide the means to progress effectively to clinical trials, with a strong view to develop efficacious and safe medicines ready for market access.

Julia Berretta, Chief Executive Officer of Genespire commented: SR-Tiget brings outstanding expertise and significant experience in developing gene therapies from bench to bedside. We believe that our strong partnership with SR-Tiget, led by internationally recognized experts Prof. Luigi Naldini and Dr. Alessio Cantore will be fundamental for Genespire to carry out its goal of translating pioneering science into transformative therapeutic solutionsfor patients.

-ENDS-

Oral presentation 1 details:

Title:

Modeling, Optimization and Comparative Efficacy of HSC- and T-cell Based Editing Strategies for Treating Hyper IgM Syndrome

Authors:

Valentina Vavassori, Elisabetta Mercuri, Genni Marcovecchio, Maria Carmina Castiello, Giulia Schiroli , Luisa Albano, Elena Fontana, Andrea Annoni, Valentina Capo, Carrie Margulies, Frank Buquicchio, Joseph Kovacs, Eugenio Scanziani, Cecilia Cotta-Ramusino, Anna Villa, Luigi Naldini, Pietro Genovese

Date and time: May 14th 2020, 3:45 PM EDT

Session: 354 Gene Therapies for Hemophilia and Immune Disorders

Abstract #937

Oral Presentation 2 Details

Title:

Investigating the stability of lentiviral vector targeted liver cells during post-natal growth for in vivo gene therapy applications

Authors:

Michela Milani, Francesco Starinieri, Cesare Canepari, Tongyao Liu, Federica Moalli, Gioia Ambrosi, Tiziana Plati, Mauro Biffi, Cesare Covino, Timothy Nichols, Matteo Iannacone, Robert Peters, Luigi Naldini, Alessio Cantore

Date and time: May 14th 2020, 4:15 pm EDT

Session: 350 RNA Virus Vectors

Abstract #911

About Hyper IgM Syndrome (HIGM)

Hyper IgM is a Primary Immune Deficiency affecting 1:250,000-500,000 patients. The disease is linked to mutations in the CD40L gene, which is expressed in activated CD4 T cells, and results in impaired antibody production and innate immunity. The current standard of care is constituted by continuous Ig replacement, and antibiotic-antifungal prophylaxis, but the disease is still linked to high morbidity and reduced life expectancy. Allogeneic hematopoietic stem cell transplant (HSCT) is potentially curative, but is limited by matched donor availability and is associated with high risk of graft versus host disease, infections and death. Thus, improved therapeutic alternatives are strongly needed.

About Genespire

Genespire is a biotechnology company focused on the development of transformative gene therapies for patients affected by genetic diseases, particularly primary immunodeficiencies and inherited metabolic diseases. Based in Milan, Italy, Genespire was founded in March 2020 by the gene therapy pioneer Prof. Luigi Naldini and Dr. Alessio Cantore, Fondazione Telethon and Ospedale San Raffaele. It is a spin-off of SR-Tiget, a world leading cell and gene therapy research institute and is backed by Sofinnova Partners. http://www.genespire.com

About SR-Tiget

Based in Milan, Italy, the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) is a joint venture between the Ospedale San Raffaele and Fondazione Telethon. SR-Tiget was established in 1995 to perform research on gene transfer and cell transplantation and translate its results into clinical applications of gene and cell therapies for different genetic diseases. Over the years, the Institute has given a pioneering contribution to the field with relevant discoveries in vector design, gene transfer strategies, stem cell biology, identity and mechanism of action of innate immune cells. SR-Tiget has also established the resources and framework for translating these advances into novel experimental therapies and has implemented several successful gene therapy clinical trials for inherited immunodeficiencies, blood and storage disorders, which have already treated >115 patients and have led through collaboration with industrial partners to the filing and approval of novel advanced gene therapy medicines.

About Fondazione Telethon

Fondazione Telethon is a non-profit organisation created in 1990 as a response to the appeals of a patient association group of stakeholders, who saw scientific research as the only real opportunity to effectively fight genetic diseases. Thanks to the funds raised through the television marathon, along with other initiatives and a network of partners and volunteers, Telethon finances the bestscientific research on rare genetic diseases, evaluated and selected by independent internationally renowned experts, with the ultimate objective of making the treatments developed available to everyone who needs them. Throughout its 30 years of activity, Fondazione Telethon has invested more than 528 million in funding more than 2.630 projects to study more than 570 diseases, involving over 1.600 scientists. Fondazione Telethon has made a significant contribution to the worldwide advancement of knowledge regarding rare genetic diseases and of academic research and drug development with a view to developing treatments. For more information, please visit:www.telethon.it

About Ospedale San Raffaele

Ospedale San Raffaele (OSR) is a clinical-research-university hospital established in 1971 to provide international-level specialised care for the most complex and difficult health conditions. OSR is part ofGruppo San Donato, the leading hospital group in Italy. The hospital is a multi-specialty center with over 60 clinical specialties; it is accredited by the Italian National Health System to provide care to both public and private, national and international patients. Research at OSR focuses on integrating basic, translational and clinical activities to provide the most advanced care to our patients. The institute is recognized as a global authority in molecular medicine and gene therapy, and is at the forefront of research in many other fields. Ospedale San Raffaele is a first-class institute which treats many diseases and stands out for the deep interaction between clinical and scientific area. This makes the transfer of scientific results from the laboratories to the patients bed easier. Its mission is to improve knowledge of diseases, identify new therapies and encourage young scientists and doctor to grow professionally. For more information, please visit:www.hsr.it

More:
Genespire and SR-Tiget announce strategic alliance for the development of transformative gene therapies for genetic diseases and disclose collaboratio...

Cell Biology

What’s This Is of Organism in Biology? – 47abc – WMDT

You will find various scientists using the languagelifetimeculture to mean the same thing.

These technological definitions of existence have been known for centuries and it has never been possible to obtain another definition of lifestyle to better suit them. These arent significant enough to impact the significance of those words, although Ofcourse there are gaps among kinds and living organisms. The wordaliveliving things have been utilized to spell out an assortment of household objects along with unique sorts of non-living organisms as well https://expert-writers.net/thesis-help as course its really just a generalization.

These definitions of life have found software even fiction. As an instance, exactly how frequently have you ever heard that the termcell and have wondered exactly what this supposed? A mobile can be a basic unit in life, plus it is a superior notion to specify just what a cell is in terms of life. It does not have to be cells surviving cells, as cells are divided into the two categories of animal and fungus tissues.

The expression organism is also a significant element in mathematics because it relates to various kinds of living programs in a particular environment. Nevertheless, the organism significance is employed for just about any type of system which lives in a given atmosphere. Because theyve similar intentions from mathematics the organism meaning is used at the same manner since the concept of the cell.

The organism meaning in chemistry describes a lodestar.asu.edu set of living organisms which can be categorized based on similarities or similarities or which may be exceptional. It indicates some thing which can be categorized based on a unit or cells presence . Only because they reproduce without limitation, but minus a definition these tissues are rather vital in character. These cells then replacingthemselves over again and then replicate by splitting as well as in a few scenarios it is possible to divide a single cell.

When it has to do with cells, then they could divide by dispersing out or by enlarging in size and spreading out on a perpendicular axis or enlarging horizontally. These mechanisms are determined by the surroundings. Although other organisms do not have some function for mobile division, some creatures utilize the mobile division to reproduce.

The receptor significance in mathematics is significant as it supplies a foundation for contrast and comparison. expert essay writers It will make it possible to think about the distinctions in between also the similarities, their own variances, and organisms that may be seen between these organisms. Sir Francis Galton, that was the very first to ever use the term in his book Animal Magnetism discovered and defined the organism meaning in biology.

The receptor significance in research has been employed to explain a variety of phenomena, by the development of people even and to the gaps between both plants and animals between human beings and other organisms. This is of an organism used in mathematics may be overall as you are able to see plus it may likewise be specific. At an identical time it may be equally special and general in certain scenarios.

See the rest here:
What's This Is of Organism in Biology? - 47abc - WMDT

Cell Biology

$10 million gift accelerates research to improve cancer therapies, extend benefits to more patients – Newswise

Newswise Researchers at the University of Chicago Medicine will come together to develop personalized therapies for hard-to-treat cancers, thanks to a $10 million gift from the Jonas family.

The gift establishes the David and Etta Jonas Center for Cellular Therapy at UChicago Medicine, named for David Jonas and his late wife, Etta.

The center unites a team of experts dedicated to improving cellular therapy, especially T-cell treatments like CAR (chimeric antigen receptor) T-cell therapy, an emerging form of cancer treatment. CAR T-cell therapy works by supercharging patients white blood cells to seek out and destroy cancer cells. Although this therapy has, in some cases, led to complete remission, it is not always successful and is currently limited to treating certain blood cancers.

Through the David and Etta Jonas Center for Cellular Therapy, researchers at UChicago Medicine will work to overcome these challenges and realize the full potential of cellular therapy. This includes efforts to improve the therapys overall effectiveness and extend its benefits to a much broader group of patients, including those with cancers that are currently difficult to treat.

I was impressed by UChicago Medicines multidisciplinary research program and commitment to attaining tangible outcomes that will really serve cancer patients, Jonas said. They have all the key elements for a successful research program: experience in clinical trials, access to the most leading-edge technology, a tremendous track record in attracting scientific talent, and a strong team to lead the program.

Developing truly personalized therapies T-cells patrol our bodies, searching for signs of infection and disease. When T-cells detect an abnormal protein on the surface of a cell, called an antigen, they latch onto it with a matching receptor. Like puzzle pieces, the antigen and T-cell receptor bind together, triggering an immune response that destroys the cell.

Some cancers, however, develop ways to trick the immune system, such as by disguising themselves as healthy cells or by shutting down the immune response altogether. CAR-T cell therapy helps to resolve this by modifying patients T-cells in the lab, so they can better recognize and target cancer-specific antigens.

However, there isnt a one-size-fits-all approach to targeting antigens since they are unique to each patient and his or her tumor; nor is there a reliable method for predicting which antigens a given tumor will express. To address these challenges, Hans Schreiber, MD, PhD, professor of pathology at the University of Chicago, has developed a new method for personalized T-cell therapy. By characterizing a patients T-cell receptors, he is able to engineer a customized therapy that accurately targets the tumors unique antigens.

This highly personalized approach to T-cell therapy can safely target cancer cells, without damaging healthy tissue. It also has the potential to treat other cancer typesbeyond blood cancersincluding hard-to-treat solid tumors, like pancreatic and ovarian cancers. With new investments in infrastructure and expertise, the Jonas Center will accelerate this research effort and develop this therapy for clinical trials for patients with metastatic solid tumors, through a collaboration with Michael Bishop, MD, professor of medicine and director of the Cellular Therapy Program, and Amittha Wickrema, PhD, professor of medicine.

This gift will allow us to translate these groundbreaking discoveries made in the laboratory into novel cancer therapies, which have the potential to treat not just blood cancers, but also solid tumors, said Kenneth Polonsky, MD, dean and executive vice president for medical affairs at the University of Chicago. If we can accomplish even part of that, it will be a major transformation in cancer therapy that will change the lives of many patients here in the United States and around the world.

Improving response ratesWhile some patients have an excellent response to CAR T-cell therapy, others do not respond or relapse shortly after undergoing treatment.

Bishop is leading an effort to identify factors that contribute to the therapys success, which is showing response rates greater than 90% for patients with acute lymphoblastic leukemia (ALL).

Bishop suspects that the fitness of patients T cells may determine if, and how well, they respond to therapy. Like a soccer team, it is important that patients T cells are not only fit enough to successfully take on their opponent (the cancer), but they must also be able to sustain their energy long enough to defeat their opponent and win the game.

By identifying the qualities that make T cells fit, Bishop and his colleagues seek to predict how a patient will respond to the therapy in advance. This way, a patients T cells could be sequenced prior to undergoing treatmentallowing physicians to gauge if their immune system will be able to wage a successful attack against the cancer. In cases where the patients T cells are deemed unfit, the researchers aim to develop interventions to improve their fitness.

This is the most exciting time in my entire career, Bishop said. We finally have hope for patients who previously didnt have hope. And now we are working to improve upon these results. Within the next 10 years, I think these treatments are going to become more effective, less toxic, and most importantly, will give new options to a broader scope of patients.

Building an infrastructure for success The Jonas familys gift will provide essential funding to advance research initiatives, while also putting in place the necessary infrastructure to sustain a successful research enterprise in the years to come. To this end, the Jonas Center will allow for: Recruitment of leading experts in T-cell biology and cell engineering Expansion of research and clinical trials infrastructure Acquisition of specialized technology and equipment necessary to translate discoveries made in the laboratory to the clinic An annual lecture that brings together leaders in cellular therapy and fosters dissemination of the latest innovations in the field

We feel extremely proud and appreciative to have the opportunity to partner with the University of Chicago in this effort, Jonas said. We see our contribution as the seed for building a robust program that will lead to the next breakthrough in cancer therapy.

This gift represents the single largest donation to UChicago Medicine for cellular therapy research.###

About David Jonas David Jonas is the founder, president and CEO of JVC Investment Partners. He is also the founder, former chairman and CEO of PharMEDium Healthcare Corporation. Prior to founding PharMEDium, David was a co-founder and chief operating officer of Renal Therapy Services Worldwide Inc.

About the University of Chicago Medicine & Biological SciencesThe University of Chicago Medicine, with a history dating back to 1927, is one of the nations leading academic health systems. It unites the missions of the University of Chicago Medical Center, Pritzker School of Medicine and the Biological Sciences Division. Together with Harvey-based Ingalls Memorial, UChicago Medicine has 1,286 licensed beds, nearly 1,300 attending physicians, about 3,200 nurses and over 1,100 residents and fellows.

Visit UChicago Medicines health and science news blog at http://www.uchicagomedicine.org/forefront.Twitter @UChicagoMedFacebook.com/UChicagoMed

Read more:
$10 million gift accelerates research to improve cancer therapies, extend benefits to more patients - Newswise

Cell Biology

More than 70 percent of coronavirus cases in Israel came from US: study | TheHill – The Hill

More than 70 percent of coronavirus cases in Israel came from the U.S., according to a study released Monday by Tel Aviv University.

Researchers mapped the spread of the virus by decoding genomic sequences of virus strains in determining thatthe majority of Israels cases originated in the U.S., Adi Stern of the School of Molecular Cell Biology and Biotechnology at the university told The Jerusalem Post.

The researchersused about 4,700 sequences taken globally to compare local patient sequences.

The study, published on medRxiv.org, found the remaining infections in Israel came from Europe and elsewhere, including 8 percent from Belgium, 6 percent from France, 5 percent from England and 3 percent from Spain. The researchers concluded that all infections came from abroad.

Israel did not shut down travel from the U.S. and most visitors from abroad until March 9, while flights from Europe and other areas of the world shut down between Feb. 26 and March 4.

There was this gap in policy, and this gap allowed people to return from the US who thought that they could go wherever they wanted, so they probably spread the virus that way, Stern told the Post.

Some infections originating from Europe and Southeast Asia also entered the country, but those patients were quarantined early, limiting the coronaviruss spread, the Post reported.

The researchers determined that between 1 percent and 10 percent of patients spread about 80 percent of cases at super-spreading events, such as large parties or other social gatherings. But the study determined that social distancing efforts did reduce the amount of spread.

Before the study, health officials depended on patient feedback in order to track the spread.

Tel Aviv University was assisted by 11 other health institutes or universities, including Emory University, in the study.

Israel has confirmed 16,643 cases in the country, leading to at least 276 deaths, according to data from Johns Hopkins University.

See the original post:
More than 70 percent of coronavirus cases in Israel came from US: study | TheHill - The Hill

Cell Biology

Research Associate at the Chair of Applied Zoology job with TECHNISCHE UNIVERSITAT DRESDEN (TU DRESDEN) | 207131 – Times Higher Education (THE)

At TU Dresden, Faculty of Biology, Institute of Zoology, the Chair of Applied Zoology offers a project position as

Research Associate

(Subject to personal qualification employees are remunerated according to salary group E 13 TV-L)

starting 01.08.2020, until 31.12.2021. The period of employment is governed by 2 (2) Fixed Term Research Contracts Act (Wissenschaftszeitvertragsgesetz-WissZeitVG). The position offers the chance to obtain further qualification. Balancing family and career is an important issue. The post is basically suitable for candidates seeking part-time employment.

Tasks: In a BMWi-funded national cooperation project, you shall investigate expression profiles of a carp cell line and quantify the expression of specific signaling network components (e.g. endocrine disruption). You shall identify regulatory sequences of suited candidate genes and test their functionality in reporter assays. Such in vitro data shall be compared with in vivo data of other fish species. The signal networks shall be compared to data of mammals with respect to ecotoxicological relevance. The project covers a wide range of techniques of molecular and cellular biology and include NGS transcriptomics, in silico analysis, cloning and qPCR. We offer state of the art facilities and expect your participation in presentation and publication of the results.

Requirements: university degree in biology or a closely related field. We are seeking for a highly motivated scientist with knowledge of molecular biology, cell biology and microscopic techniques. Experience in bioinformatics and the analysis of RNAseq data are highly desirable. An independent working style and the handling of animals is expected. The national cooperation project requires team spirit and solid knowledge of the German or the English language.

Applications from women are particularly welcome. The same applies to people with disabilities.

Please send your application documents using code number 235 in the subject header until 09.06.2020 (stamped arrival date of the university central mail service applies) to: TU Dresden, Fakultt Biologie, Institut fr Zoologie, Professur fr Angewandte Zoologie, Herrn Dr. Alexander Froschauer, Helmholtzstr. 10, 01069 Dresden or via the TU Dresden SecureMail Portal https://securemail.tu-dresden.de by sending it as a single pdf document to alexander.froschauer@tu-dresden.de. Please submit copies only, as your application will not be returned to you. Expenses incurred in attending interviews cannot be reimbursed.

Reference to data protection: Your data protection rights, the purpose for which your data will be processed, as well as further information about data protection is available to you on the website: https://tu-dresden.de/karriere/datenschutzhinweis

Please find the german version under:

https://tu-dresden.de/stellenausschreibung/7670

View original post here:
Research Associate at the Chair of Applied Zoology job with TECHNISCHE UNIVERSITAT DRESDEN (TU DRESDEN) | 207131 - Times Higher Education (THE)

Cell Biology

New Stem Cell-Based Topical Solution Helps Bald People Regrow Hair – SciTechDaily

A clinical trial showed the ability of a stem cell-based topical solution to regrow hair in people with male/female pattern baldness.

The results of a clinical trial released today (May 18, 2020) in STEM CELLS Translational Medicinedemonstrate how a topical solution made up of stem cells leads to the regrowth of hair for people with a common type of baldness.

Androgenetic alopecia (AGA) commonly known as male-pattern baldness (female-pattern baldness in women) is a condition caused by genetic, hormonal and environmental factors. It affects an estimated 50 percent of all men and almost as many women older than 50. While it is not a life-threatening condition, AGA can lower a persons self-esteem and psychological well-being. There are a few FDA-approved medications to treat hair loss, but the most effective can have side effects such as loss of libido and erectile dysfunction. Therefore, the search continues for a safer, effective treatment.

Adipose tissue-derived stem cells (ADSCs) secrete several growth hormones that help cells develop and proliferate. According to laboratory and experimental studies, growth factors such as hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), insulin-like growth factor (IGF) and platelet-derived growth factor (PDGF) increase the size of the hair follicle during hair development.

A more enriched adipose-derived stem cells-constituent extract (ADSC-CE) with stem cell proteins is obtained by disruption of the ADSC membrane using a low frequency of ultrasound wave. Credit: AlphaMed Press

Recent studies have shown that ADSCs promote hair growth in both men and women with alopecia. However, no randomized, placebo-controlled trial in humans has explored the effects and safety of adipose-derived stem cell constituent extract (ADSC-CE) in AGA. We aimed to assess the efficacy and tolerability of ADSC-CE in middle-aged patients with AGA in our study, hypothesizing that it is an effective and safe treatment agent, said Sang Yeoup Lee, M.D., Ph.D., of the Family Medicine Clinic and Research Institute of Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital in South Korea. He led the group of researchers, which also included colleagues from Pusan National University School of Medicine, Pusan National University Yangsan Hospital and T-Stem Co., Ltd.

The team recruited 38 patients (29 men and nine women) with AGA and assigned half to an intervention group that received the ADSC-CE topical solution and half as a control group that received a placebo. Twice daily, each patient applied the ADSC-CE topical solution or placebo to their scalp using their fingers.

At the end of 16 weeks, the group that received the ADSC-CEs had a significant increase in both hair count and follicle diameter, reported the studys senior author, Young Jin Tak, M.D., Ph.D.

Dr. Lee added, Our findings suggest that the application of the ADSC-CE topical solution has enormous potential as an alternative therapeutic strategy for hair regrowth in patients with AGA, by increasing both hair density and thickness while maintaining adequate treatment safety. The next step should be to conduct similar studies with large and diverse populations in order to confirm the beneficial effects of ADSC-CE on hair growth and elucidate the mechanisms responsible for the action of ADSC-CE in humans.

For the millions of people who suffer from male-pattern baldness, this small clinical trial offers hope of a future treatment for hair regrowth, said Anthony Atala, M.D., Editor-in-Chief ofSTEM CELLS Translational Medicineand director of the Wake Forest Institute for Regenerative Medicine. The topical solution created from proteins secreted by stem cells found in fat tissue proves to be both safe and effective. We look forward to further findings that support this work.

###

Reference: A Randomized, Double-blind, Vehicle-Controlled Clinical Study of Hair Regeneration Using Adipose-Derived Stem Cell Constituent Extract in Androgenetic Alopecia 18 May 2020, STEM CELLS Translational Medicine.DOI: 10.1002/sctm.19-0410

AboutSTEM CELLS Translational Medicine:STEM CELLS Translational Medicine(SCTM), co-published by AlphaMed Press and Wiley, is a monthly peer-reviewed publication dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices. SCTM is the official journal partner of Regenerative Medicine Foundation.

About AlphaMed Press: Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes two other internationally renowned peer-reviewed journals:STEM CELLS, celebrating its 38th year, is the worlds first journal devoted to this fast paced field of research.The Oncologist, also a monthly peer-reviewed publication, entering its 25th year, is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. All three journals are premier periodicals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines.

Read more here:
New Stem Cell-Based Topical Solution Helps Bald People Regrow Hair - SciTechDaily

Cell Biology

COVID-19 Impact on Human Embryonic Stem Cell Market 2020 Regional Outlook, Latest Trend, Share Analysis, Growth, Application and Forecast to 2027 -…

The Covid-19 (coronavirus) pandemic is impacting society and the overall economy across the world. The impact of this pandemic is growing day by day as well as affecting the supply chain. The COVID-19 crisis is creating uncertainty in the stock market, massive slowing of supply chain, falling business confidence, and increasing panic among the customer segments. The overall effect of the pandemic is impacting the production process of several industries including Life science Industry, and many more. Trade barriers are further restraining the demand- supply outlook. As government of different regions have already announced total lockdown and temporarily shutdown of industries, the overall production process being adversely affected; thus, hinder the overall Human Embryonic Stem Cell market globally. This report on Human Embryonic Stem Cell market provides the analysis on impact on Covid-19 on various business segments and country markets. The report also showcase market trends and forecast to 2027, factoring the impact of Covid -19 Situation.

The human embryonic stem cells are obtained from the undifferentiated inner mass cell of the human embryo and human fetal tissue. The human embryonic stem cell can replicate indefinitely and produce non-regenerative tissue such as myocardial and neural cells. This potential of human embryonic stem cell allows them to provide an unlimited amount of tissue for transplantation therapies to treat a wide range of degenerative diseases. Hence, human embryonic stem cells are used in the treatment of various diseases such as Alzheimers disease, cancer, blood and genetic disorders related to the immune system and others.

Get the inside scope of the Sample report @https://www.theinsightpartners.com/sample/TIPRE00005165/

MARKET DYNAMICSThe global human embryonic stem cell market is expected to grow in upcoming years, factors driving the growth of market are rise in incidences of neurological disorders, increase in investment by government and other organization for research activities, awareness among people about stem cell therapeutic potency for disease treatment. On the other hand emerging stem cell banking services is expected to offer lucrative opportunities in growth of human embryonic stem cell market.

The report also includes the profiles of key human embryonic stem cell market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

Key Competitors In Market are

TOC pointsof Market Report:

Market size & shares

Market trends and dynamics

Market Drivers and Opportunities

Competitive landscape

Supply and demand

Technological inventions in industry

Marketing Channel Development Trend

Market Positioning

Pricing Strategy

Brand Strategy

Target Client

MARKET SCOPE

The Global Human Embryonic Stem Cell Market Analysis to 2027 is a specialized and in-depth study with a special focus on the global medical device market trend analysis. The report aims to provide an overview of human embryonic stem cell market with detailed market segmentation by product type, application, end users and geography. The global human embryonic stem cell market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading human embryonic stem cell market players and offers key trends and opportunities in the market.

Market segmentation:

Human Embryonic Stem Cell Market to 2027 Global Analysis and Forecasts By Product Type (Totipotent Stem Cell, Pluripotent Stem Cell, Unipotent stem Cell); Application (Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering, Toxicology Testing); End User (Therapeutics Companies, Cell & Tissue Banks, Tools & Reagents Companies, Others) and Geography

By Geography North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. And 13 countries globally along with current trend and opportunities prevailing in the region.

The target audience for the report on the market

Manufactures

Market analysts

Senior executives

Business development managers

Technologists

R&D staff

Distributors

Investors

Governments

Equity research firms

Consultants

Click to buy full report with all description:-https://www.theinsightpartners.com/buy/TIPRE00005165/

About Us:

The Insight Partnersis a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are committed to provide highest quality research and consulting services to our customers. We help our clients understand the key market trends, identify opportunities, and make informed decisions with our market research offerings at an affordable cost.

We understand syndicated reports may not meet precise research requirements of all our clients. We offer our clients multiple ways to customize research as per their specific needs and budget

Contact Us:

The Insight Partners,

Phone: +1-646-491-9876

Email:[emailprotected]

Here is the original post:
COVID-19 Impact on Human Embryonic Stem Cell Market 2020 Regional Outlook, Latest Trend, Share Analysis, Growth, Application and Forecast to 2027 -...

Cell Biology

As the First Smallpox Vaccine Turns 224, A Look at How It Started – The Great Courses Daily News

By Jonny Lupsha, News Writer

The website The History of Vaccines said that the first smallpox inoculation came about as a test of a hypothesis that a cowpox infection could protect someone from getting the smallpox disease. On May 14, 1796, [Edward] Jenner inoculated eight-year-old James Phipps with matter from a cowpox sore on the hand of milkmaid Sarah Nelmes, the website said. Phipps suffered a local reaction and felt poorly for several days but made a full recovery. In July 1796, Jenner inoculated Phipps with matter taken from a fresh human smallpox sore, as if he were variolating the boy, in an attempt to challenge the protection from cowpox. Phipps remained healthy.

The 18th-century history of inoculating against smallpox also includes a young George Washington.

In 1776, the colonies that would become the United States of America faced an enemy that George Washington considered to be more dangerous than the British army.

Smallpox had ravaged General Horatio Gatess American Northern Army, said Dr. David Sadava, Adjunct Professor of Cancer Cell Biology at the City of Hope Medical Center. Of 10,000 troops, over half of them got smallpox, and the military campaign had to be suspended for a month.

Dr. Sadava said that Washington spoke of smallpox from experience. In his teenage years, Washington took his half-brother Lawrence to Barbados to help with Lawrences tuberculosis. Although the trip failed to help Lawrence, George contracted smallpox and learned of its dangers. By the time of the Revolutionary War, he had come to appreciate how serious smallpox could be. He chose to order his troops to be inoculated against the illness the following year.

The 1777, inoculation ordered by Washington was the first-known inoculation of an army, and it worked pretty well, Dr. Sadava said. Casualties to smallpox were greatly reduced and history tells us that the colonists, of course, won the Revolutionary War.

George Washington contracted smallpox when he was a teenager, but he obviously lived for a long time afterward due to his bodys vigilant immune system.

Washingtons immune system, the system that fights disease, fought off the infection in several steps, Dr. Sadava said. After the smallpox virus entered Washingtons body, some white blood cells called phagocytes engulfed the virus. They digested it to small pieces, chopped it up, and they presented some of these protein fragments of the virus on their cell surface.

After this, Dr. Sadava said, other white blood cells flagged the smallpox virus and set a series of events in motion that saved Washingtons life. These events included sending cells called killer T-cells into the fight which targeted any cell in Washingtons body that carried smallpox.

Still other white blood cells, called B-cells, made antibodiesthese are blood proteins that would bind up any viruses that were outside Washingtons cells, that hadnt infected a cell but were in the bloodstream, for example, Dr. Sadava said. So these B-cells made a whole army that would make antibodies that would bind them up. This two-pronged attackcells to kill infected tissue and antibodies to bind up free virusesswiftly reduced the infection to a mild one in Washingtons case.

Dr. Sadava said that once smallpox was eradicated from Washingtons body, the remaining cells that stood guard to watch for smallpox were called memory cells, and they were the same types of cells that were key to inoculating the army. He said that when dead smallpox viruses from the pus of smallpox victims was put into the cut skin of Continental Army soldiers, the viruses looked enough like their live counterparts to spur the immune system into producing the T- and B-cells required to fight the virus.

Today, smallpox has mostly been eradicated through vaccination. It wouldnt have been possible without Edward Jenners cowpox experiment and George Washingtons caution over the disease.

Dr. David Sadava contributed to this article. Dr. Sadava is Adjunct Professor of Cancer Cell Biology at the City of Hope Medical Center and the Pritzker Family Foundation Professor of Biology, Emeritus, at The Claremont Colleges. He earned a B.S. with first-class honors in biology and chemistry from Carleton University and a Ph.D. in Biology from the University of California, San Diego.

See the original post:
As the First Smallpox Vaccine Turns 224, A Look at How It Started - The Great Courses Daily News

Cell Biology

Study finds different types of human white fat cells – Medical News Today

Discovering that white fat cells are not all the same may help researchers better understand the role of fat cells in disease.

The risks associated with white adipose tissue, or white body fat, depend to some extent on where that fat is.

For example, intra-abdominal fat (belly fat) is more likely to lead to diabetes and other metabolic conditions than white fat deposits located just beneath the skin (such as in the hips and thighs).

Now, however according to a new paper from the Joslin Diabetes Center in Boston and Boston University, both in Massachusetts it appears that there is more to it than that: There are at least two distinct classes of subcutaneous white fat cells.

A central question in our research on metabolic disease is whether white fat cells in different parts of the body, and even within a single part of the body, are different enough that some might predispose you to disease and some might not, says co-senior author C. Ronald Kahn, a physician and scientist.

Immature white fat cells do not follow a single, universal trajectory to maturity. They can develop different patterns of gene expression.

Kahn is hopeful that determining the mechanisms for these differences could lead to development of novel therapies for diabetes, obesity, and related conditions.

The paper now appears in the journal Nature Communications.

Although previous research had identified multiple types of white fat cells in mice, this is one of the first to have done so in humans.

The paper is the product of an unusual collaboration, says Kahn. According to senior co-author Simon Kasif, a biomedical engineer, The study highlights the potential of bringing interdisciplinary expertise from four laboratories to integrate biology, artificial intelligence, systems biology, and data obtained from clinical samples to catalyze discovery.

Although the study identified two different types of white fat cells, that may just be the beginning. We think this research is the tip of the iceberg if we study more samples of human fat, we will find more subtypes, says Kahn.

Single-cell RNA sequencing allows scientists to track the genetic development of single fat cells from their precursor, or preadipocyte, stage to their mature patterns of gene expression.

For this project, the researchers used white subcutaneous fat cells from a biobank of specimens that scientists had previously collected from healthy individuals.

Scientists at the Broad Institute of MIT and Harvard in Cambridge, MA, and the Joslin laboratory of Yu-Hua Tseng then performed single-cell RNA sequencing on these samples.

Researchers performed an integrated analysis of both datasets using a novel mathematical technique that helped reveal the cells patterns of gene expression. It revealed that the datasets depicted two distinct white fat cell subtypes.

To begin with, as preadipocytes, one subtype expressed much higher levels of zinc nuclear finger genes. This is a set of master regulator genes, the function of which researchers do not yet understand. However, they may help control cells maturation, say the papers authors.

In addition, at maturity, the two cell subtypes exhibited very different patterns of gene expression.

The patterns in one subtype, for example, indicated a significantly higher intake of glucose, which is an important metabolic resource.

Body fat is linked to many different conditions beyond diabetes. This research could be important for understanding the risk factors for other metabolic diseases, such as fatty liver disease and atherosclerosis, and even non-metabolic diseases that are increased by obesity, such as cancer and Alzheimers disease.

C. Ronald Kahn

That white fat cells can be different from each other also fits with another growing area of research.

According to Kasif: Metabolic diseases are highly associated with environmental factors. This work supports the relatively understudied hypothesis that environmental factors may modify the trajectory of how cells develop and our understanding of how this process may influence biology and metabolic disease.

View post:
Study finds different types of human white fat cells - Medical News Today